← ARWR: big moves and long-term fundamentals中文

Arrowhead Pharmaceuticals: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 12, 2026 · Reflects: 10-K FY2026

Disclosure: one or more of our editors own shares of Arrowhead Pharmaceuticals (ARWR) as a long-term investment. Disclosure: one or more of our editors own shares of Madrigal Pharmaceuticals (MDGL), named on this page, as a long-term investment. This page is information, not investment advice.

Sources used most:

1. In one paragraph

Last updated Nov 12, 2026. Reflects the 10-K FY2026.

Arrowhead develops RNA-interference (RNAi) medicines: drugs that target a gene’s messenger RNA so that cells make much less of a disease-related protein. Almost all of its revenue still comes from partners. Its first own drug, Redemplo (plozasiran), was approved on Nov 18, 2025; product sales were $6.6M in FY2026, about 1.5% of revenue.

  • Arrowhead reports one segment.
  • Revenue model: partners that license its drug candidates pay upfront fees, milestone payments, annual fees and research reimbursements. Since late 2025 Arrowhead also sells its own drug.
  • FY2026 revenue was $450.8M: $316.9M from Sarepta (70%), $89.0M from Novartis (20%), $25.0M from Madrigal (6%), $13.3M from Sanofi (3%) and $6.6M of Redemplo sales (1.5%) (our calculation)1. These are recognised revenues, not cash receipts (10-K FY2026, note 2).
  • FY2025 revenue was $829.4M, 84% of it from Sarepta.
  • Own drug: Redemplo was approved by the FDA on Nov 18, 2025 for familial chylomicronemia syndrome (FCS), a rare disease of very high triglycerides (blood fats). Arrowhead sells it itself in the US through a specialty pharmacy.
  • Other approvals: the EU, Canada, Australia, China (sold there by Sanofi, which pays Arrowhead royalties) and the UK (October 2026) (10-K FY2026, note 2).
  • Next step: Arrowhead has filed to extend plozasiran to severe hypertriglyceridemia (sHTG), a far larger group of patients, and is preparing for a potential US launch in the second quarter of 2027 (company).

2. Story so far

Last updated Nov 12, 2026. Reflects filings and company releases through Nov 12, 2026.

In short: For most of its history Arrowhead funded itself by licensing drug candidates to larger companies, selling shares, selling future royalties and, from 2024, borrowing. A 2024 deal with Sarepta brought $825M in cash and stock, and in November 2025 the FDA approved Arrowhead’s first own drug, Redemplo, for a rare disease. In 2026 it raised $930M, reported Phase 3 results in severe hypertriglyceridemia and filed for that larger use, and replaced its costly loan with a cheaper one.

Date Milestone Source
Nov 22, 2021 Licenses its MASH (fatty-liver disease) candidate, now GSK-4532990, to GSK for $120.0M upfront; $100.0M more is due when GSK doses the first Phase 3 patient 10-K FY2026, note 2
Nov 2022 Sells its future royalties on olpasiran (licensed to Amgen) to Royalty Pharma for $250.0M upfront plus up to $160.0M in milestones ($50.0M received in 2024); Arrowhead never repays this in cash 10-K FY2026, note 14
Jan 2024 Sells 15.79M shares at $28.50, raising $450.0M gross 10-K FY2024, note 6
Aug 7, 2024 Borrows $400.0M from lenders led by Sixth Street; interest of 15% a year is added to the loan (paid in kind) rather than paid in cash, and the loan is secured on substantially all assets 10-K FY2026, note 15
Nov 25, 2024 ★ Signs a licensing deal with Sarepta for neuromuscular and other rare-disease programmes: $500.0M upfront plus a $325.0M share purchase at $27.25, both received in February 2025, plus $250.0M of annual fees over five years and milestones 10-K FY2026, notes 2 and 6
Aug 2025 Visirna sells its Greater China rights to plozasiran to Sanofi for $130.0M upfront; Arrowhead takes back 2.66M of its shares from Sarepta for $50.0M of a $100.0M milestone payment 10-K FY2026, notes 2 and 6
Aug 29, 2025 Licenses ARO-SNCA (Parkinson’s disease, preclinical) and further brain-disease targets to Novartis; $200.0M upfront received Oct 23, 2025 8-K, Sep 2, 2025; 10-K FY2026, note 2
Sep 11, 2025 Ionis sues Arrowhead in federal court in California, claiming that commercialising plozasiran infringes its ’333 patent 10-K FY2026, note 7
Nov 18, 2025 ★ FDA approves Redemplo (plozasiran) for FCS Release (8-K)
Jan 7–12, 2026 Raises $930M gross: $230M in shares and pre-funded warrants (rights to receive shares for a nominal exercise price) at $64.50, and $700.0M of 0% convertible notes (debt that can be converted into shares under set conditions) due 2032 (conversion price about $87.07) 8-K, Jan 9; 8-K, Jan 12; 10-K FY2026, notes 6 and 16
May 4–7, 2026 Licenses ARO-PNPLA3 (MASH) to Madrigal ($25.0M upfront, up to $975.0M in milestones); lowers Redemplo’s US list price to $45,000 a patient a year, to apply to FCS and to sHTG if approved Q2 FY2026 release
Jul 22, 2026 ★ Phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran in sHTG meet their main goal and all prespecified secondary goals; median triglyceride falls of 79% and 81%, and 78% fewer acute pancreatitis events than placebo across the trials (company) Business Wire release
Aug 2026 Pays $215.0M for an FDA priority review voucher (a transferable right to a faster review), agreed Jul 31 10-K FY2026, cash flow statement; release, Oct 7
Oct 7, 2026 ★ FDA admits the planned sHTG filing into its Split Real Time Application Review (STAR) pilot, which gives a 6-month priority review without using the voucher; Arrowhead keeps the voucher (company) Business Wire release
Oct 14, 2026 Reports interim early-stage data for ARO-MAPT, a brain-targeted candidate for tau-related diseases: mean tau reductions in spinal fluid of up to 73% in healthy volunteers (company) Business Wire release
Nov 2, 2026 Refinances the Sixth Street loan: a new $400.0M loan at three-month Term SOFR (the Secured Overnight Financing Rate, a US dollar borrowing benchmark) plus 5.50 percentage points, paid in cash and due Nov 2, 2031, repays the old one for about $404.4M, about $68M less than the 2.0x payoff the old terms required 8-K, Nov 4; 10-K FY2026, note 19
Nov 9, 2026 Board moves the fiscal year end from Sep 30 to Dec 31, effective Jan 1, 2027 10-K FY2026, note 19
By Nov 12, 2026 Submits the sHTG supplemental application (sNDA) to the FDA (company; submission date not given) FY2026 results release

Start of our coverage: this page (Oct 28, 2026). We have not yet published an article on Arrowhead.

3. Latest quarter: did the story change?

Last updated Nov 12, 2026. Reflects Q4 FY2026 (quarter ended Sep 30, 2026; 10-K filed Nov 12, 2026), derived as the full year less the first nine months, and releases to Nov 12, 2026.

Bottom line: According to its filings and releases, Arrowhead’s own drug sales kept growing from a small base, the sHTG filing went in as planned (the FDA’s decision is still to come) and the loan was refinanced on cheaper, looser terms, but partner revenue fell, the $215.0M voucher widened the quarterly loss and cash resources ended the year at $1,193.0M.

Driver Last quarter → this quarter Management: before → now Signal
Redemplo sales (our calculation)2 Q3 FY2026 about $2.4M → Q4 about $3.1M Prescription volume “roughly doubled” in Q3 and more than 400 prescribers (Aug 4) → new-to-brand prescriptions +63% quarter on quarter, 950 since launch by Sep 30 and 300 more since; about 50–60 a week; more than 640 prescribers, now over 860 (FY2026 release) Better
Partner revenue Q3 $72.9M (including a one-off $25.0M Madrigal upfront) → Q4 $34.7M; Sarepta $26.4M → $19.3M, Novartis $20.2M → $14.1M (our calculation)2 Sarepta’s take-over of some clinical programmes (step-in right exercised in Q2) reduces the research work it reimburses; the Q3 cumulative adjustment was “not material” (10-K, note 2) Worse
Spending, loss and cash Operating expenses $245.3M → $474.4M, of which $215.0M was the voucher ($259.4M without it); net loss attributable to Arrowhead $194.3M → $428.0M (our calculation)2; cash, cash equivalents and investments Jun 30 $1,602.0M → Sep 30 $1,193.0M (our calculation)3 (as the company presents its cash resources) No numeric spending guidance; liquidity sufficient for “at least the next twelve months” (Aug 4) → the same wording, from the 10-K’s Nov 12 issue date (10-K, MD&A) Worse
Sixth Street loan 15% interest added to the loan; part of partner and product receipts had to be used to prepay it; payoff of at least 2.0x the amount funded Refinanced Nov 2: $400.0M at SOFR plus 5.50%, paid in cash; no sweep of partner or product receipts; a $68M discount to the 2.0x payoff; cash floor cut to $125.0M from $150.0M (8-K, Nov 4) Better
sHTG filing sNDA “by year-end 2026”, with a 6-month STAR priority review (Oct 7) sNDA submitted; preparing for a potential US launch in sHTG in the second quarter of 2027 (Nov 12); the review outcome is not yet known Watch

Unresolved questions: how Redemplo’s net price compares with its $45,000 list price; how large the sHTG launch spending will be; and how much cash interest the new loan will cost as rates move.

4. Buybacks vs real dilution (5 years)

Last updated Nov 12, 2026. Reflects the equity statements in the 10-K FY2023 and 10-K FY2026.

Dilution in one line: common shares outstanding rose 35% from Sep 30, 2021 to Sep 30, 2026, about 6.3% a year compounded. If you owned 1% of Arrowhead on Sep 30, 2021, you would own about 0.74% on Sep 30, 2026 without buying more (our calculation)4. Shares returned by Sarepta offset about 7% of the new common shares issued; there were no cash buybacks. Our scale: High (over 3% a year).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Sep 30, 2021 to Sep 30, 2026FY2022 +1.6%, FY2023 +1.2%, FY2024 +15.9%, FY2025 +9.1%, FY2026 +4.1%. Total +35.5% since Sep 30, 2021.0%+10%+20%+30%+40%FY2022: +1.6% in the period; +1.6% since Sep 30, 2021+1.6%FY2022FY2023: +1.2% in the period; +2.9% since Sep 30, 2021+1.2%FY2023FY2024: +15.9% in the period; +19.3% since Sep 30, 2021+15.9%FY2024FY2025: +9.1% in the period; +30.1% since Sep 30, 2021+9.1%FY2025FY2026: +4.1% in the period; +35.5% since Sep 30, 2021+4.1%FY2026+35.5%since Sep 30, 2021

Change in the period Total since Sep 30, 2021

Shares outstanding at period end (all classes): 104.3M on Sep 30, 2021, 141.3M on Sep 30, 2026, +35.5% (our calculation). A bar below zero means the count fell (net buybacks).

Common shares outstanding (issued less treasury), from the author's bridge (10-K and 10-Q equity statements); unexercised pre-funded warrants are not counted.

Arrowhead Pharmaceuticals's fiscal year ends in late September; FY2026 is the year that ended in September 2026.

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
FY2026 (Sep 30, 2026)141.3M+4.1%—$68M15%
FY2025 (Sep 30, 2025)135.7M+9.1%—$63M8%
FY2024 (Sep 30, 2024)124.4M+15.9%—$74M2083%
FY2023 (Sep 30, 2023)107.3M+1.2%—$78M32%
FY2022 (Sep 30, 2022)106.0M+1.6%—$121M50%
FY2021 (Sep 30, 2021)104.3M——$77M55%

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

How we calculated this

The largest source of new shares was share sales for cash, followed by employee equity plans. Arrowhead has made no acquisitions paid in stock and has had no note conversions in the period.

Bridge (millions of shares) FY2022 FY2023 FY2024 FY2025 FY2026 Total
Start of period 104.3 106.0 107.3 124.4 135.7 104.3
Stock pay and options (equity plans) 1.6 1.4 1.3 2.1 2.5 8.8
Share sales for cash (common stock) – – 15.8 11.9 3.1 30.8
Shares taken back from Sarepta (held in treasury) 0 0 0 −2.7 0 −2.7
End of period 106.0 107.3 124.4 135.7 141.3 141.3

Sources: 10-K FY2023 (FY2022–23), 10-K FY2026 (FY2024–26), statements of stockholders’ equity and note 6.

Share basis:

  • Arrowhead has one class of common stock and no stock split in the period. The FY2025 and FY2026 end figures are shares outstanding (issued less 2.66M treasury shares): 135.7M and 141.3M.
  • Not counted in shares outstanding: pre-funded warrants for 2.47M shares at Sep 30, 2026 (rights to receive shares for $0.001 each, with no expiry; 0.92M sold in FY2025 and 1.55M in FY2026; none exercised), which Arrowhead includes in its per-share figures.
  • Including them, the count rose 38%, about 6.6% a year, to 143.8M (our calculation)4.

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
FY2022 — — — — — — 10-K FY2023 equity statement
FY2023 — — — — — — 10-K FY2023
FY2024 — — — 15.79M $28.50 $450.0M 10-K FY2024, note 6: January 2024 public offering, gross
FY2025 2.66M (non-cash; see below) $18.79 (agreed price) $50.0M, settled by offset against a milestone Sarepta owed, not in cash 12.84M (11.93M shares + 0.92M pre-funded warrants) $27.25 $350.0M 10-K FY2026, note 6: Sarepta private placement 11,926,301 shares at $27.25 ($325.0M); pre-funded warrants for 917,441 shares at $27.25 ($25.0M)
FY2026 — — — 4.62M (3.07M shares + 1.55M pre-funded warrants) $66.23 (our calculation)5 $306.1M 10-K FY2026, note 6: January 2026 offering, 2,015,505 shares at $64.50 ($130.0M) and pre-funded warrants for 1,550,387 shares at $64.499 ($100.0M); at-the-market sales of about 1.056M shares for $76.1M gross ($72.07, our calculation)5
  • Prices are per share; Arrowhead has had no stock split in the period, so no adjustment was needed. Raised is gross proceeds before commissions and costs; derived averages are our calculation where marked (see the notes).
  • The FY2025 take-back was not a cash buyback: in August 2025 Sarepta paid $50.0M of a $100.0M milestone by returning 2,660,989 Arrowhead shares at an agreed $18.79 each; Arrowhead recorded them as treasury stock at their $53.2M fair value.
  • The Sarepta share purchase was booked at $241.4M in equity; the other $83.6M (the premium over the market price on Feb 7, 2025) was included in collaboration consideration for revenue recognition (10-K FY2026, note 2).
  • Not counted as sales for cash: option exercises (in the equity-plan row). Employees’ tax on vesting awards is not shown as buybacks; the equity statements show no shares withheld.

For reference, Nasdaq reports a closing price of $47.15 on Nov 12, 2026 (quote and historical prices); Yahoo Finance shows the same close.

No share sales were disclosed in the last quarter of FY2026 or after Sep 30, 2026. Options, stock units and the 2032 convertible notes (about 8.04M shares if all were converted) could add shares.

Possible further shares
  • After Sep 30, 2026: no share sales were disclosed in the filings and releases we reviewed (to Nov 12).
  • Potential further shares at Sep 30, 2026: options on 0.75M shares (average exercise price $33.94), restricted stock units for 5.76M shares, and about 8.04M shares if all the 2032 convertible notes were converted at about $87.07. Arrowhead bought capped calls (option contracts) for $47.9M with a cap of $119.33 a share that are intended to offset that dilution up to the cap. A further 11.42M shares were available for new awards under the 2021 plan and 2.07M under the inducement plan (10-K FY2026, notes 6, 10 and 16).
  • The refinanced loan now allows further convertible debt of up to the greater of $1.1B and 10% of Arrowhead’s market value, within an overall $2.5B cap that includes the $700.0M of notes (8-K, Nov 4).
Stock-based pay FY2022 FY2023 FY2024 FY2025 FY2026
$M 120.9 78.1 74.0 63.4 68.1
% of revenue (our calculation)6 50% 32% not meaningful (revenue $3.6M) 8% 15%

5. Profit vs cash (latest FY and TTM)

Last updated Nov 12, 2026. Reflects the 10-K FY2026. Arrowhead reports no adjusted profit measure. The latest fiscal year is also the trailing twelve months (TTM).

Arrowhead’s results swing with one-off partner payments. In FY2025 a $500M upfront payment made operating cash flow positive; in FY2026 about $485M of partner receipts arrived (including $435M of one-offs and a recurring $50M annual fee), and free cash flow was still −$283.9M. Large parts of the reported loss are interest that was not paid in cash and the $215.0M voucher, which was paid in investing cash flow.

$M FY2025 FY2026 (= TTM to Sep 30, 2026)
Revenue 829.4 450.8
Net income (loss) attributable to Arrowhead −1.6 −724.2
Net income (loss) including the minority holders of Visirna 30.1 −717.1
Adjusted metric Not reported Not reported
Operating cash flow 179.6 −271.9
Capital spending −22.7 −12.0
Free cash flow (our calculation)7 156.9 −283.9

Sorted by what each reconciling item does next:

Helps future profit or cash:

  • Deferred revenue (+$110.6M in FY2026; $113.0M still deferred at Sep 30, mainly from Novartis’s $200.0M upfront): cash received before it is recognised as revenue; the revenue will be recognised, with no new cash, as the research work is done.

Hurts future profit or cash:

  • Interest that was not paid in cash (FY2026: $58.5M on the Sixth Street loan and $33.0M on the Royalty Pharma liability): the old loan’s interest was added to the loan and paid at the Nov 2 payoff; the Royalty Pharma liability is not repayable in cash. The new loan’s interest is paid in cash every quarter, so from Q4 2026 it will lower operating cash flow.
  • Stock-based pay ($68.1M in FY2026; $63.4M in FY2025): a recurring cost that lowers reported profit; it is added back as a non-cash expense and shows up as new shares (dilution) instead.
  • Loan repayments are financing flows outside free cash flow: Arrowhead repaid $118.0M of the Sixth Street loan (including multiple-of-capital payments) in FY2026 and $201.6M in FY2025, then paid about $404.4M to retire it on Nov 2, 2026.

One-off / no lasting effect:

  • The priority review voucher: $215.0M expensed in FY2026 and paid in August 2026 in investing cash flow, so it is in the reported loss but not in free cash flow.
  • Partner cash received in FY2026, about $485M (our calculation)8, made up of $435M of one-off receipts and a recurring $50M annual fee: it lifts cash flow, and future upfront and milestone receipts depend on new agreements or contractual triggers. It includes Novartis $200.0M (Oct 2025), Sarepta’s second milestone for its type 1 myotonic dystrophy (DM1) programme, $200.0M (Jan 2026), Sarepta’s first annual fee $50.0M (Feb 2026), the China approval milestone $10.0M (Jan–Mar 2026) and Madrigal $25.0M (Jun 2, 2026).
  • Non-cash gains: FY2026 included a $19.0M gain paid in shares of an unlisted affiliate, Bisirna, and a $7.6M gain on the dilution of that holding.
The raw reconciling items
  • Interest that was not paid in cash in FY2026: $58.5M on the Sixth Street loan (15% interest added to the loan, plus accretion of the extra repayment owed to lenders) and $33.0M on the Royalty Pharma liability. Both raise the reported loss without using cash (10-K FY2026, notes 14 and 15).
  • Stock-based pay of $68.1M in FY2026 ($63.4M in FY2025) is added back.
  • The $215.0M voucher is added back in operating cash flow and shown as a purchase in investing cash flow.
  • Cash received before it is recognised as revenue: deferred revenue rose $110.6M in FY2026, mainly Novartis’s $200.0M upfront, which is recognised as the research work is done ($113.0M deferred at Sep 30, of which $21.3M non-current).
  • Partner cash in FY2026, about $485M (our calculation)8, of which $435M is one-off and $50M is Sarepta’s recurring annual fee: Novartis $200.0M (Oct 2025), Sarepta’s second DM1 milestone $200.0M (Jan 2026), Sarepta’s first annual fee $50.0M (Feb 2026), the China approval milestone $10.0M (Jan–Mar 2026) and Madrigal $25.0M (Jun 2, 2026).
  • Non-cash items in the other direction: the $19.0M gain paid in Bisirna shares and a $7.6M dilution gain, partly offset by an $11.5M loss on that equity-method holding.
  • Loan repayments are financing flows, not part of free cash flow: $118.0M of the Sixth Street loan (including multiple-of-capital payments) in FY2026 and $201.6M in FY2025.

Funding: how long without new money? (as of Sep 30, 2026, the latest filed balance sheet) At the past rate excluding one-off partner receipts, Sep 30 cash covered about 1.7 years of spending (our calculation)9. The Nov 2 refinancing used about $12.4M of cash on a net basis and replaced the old loan’s scheduled repayments with a single repayment in 2031; no committed undrawn credit is disclosed.

Funding details
  • Cash, cash equivalents (including $33.5M at Visirna, 56% owned) and available-for-sale securities: about $1,188.8M, excluding $4.2M of restricted cash. FY2026 free cash outflow was $283.9M; it includes about $485M of partner receipts (listed above). Excluding the $435.0M of them that are one-offs (Sarepta’s $50.0M annual fee recurs yearly, so it stays in), it would have been about $718.9M.
  • The company itself says it has sufficient liquidity to fund operations for “at least the next twelve months” from the issue date of its FY2026 financial statements (10-K, note 1).
  • This is based on past cash flow; spending plans can change it.

Financing items, sorted by what they do to the runway:

Extends the runway:

  • Committed undrawn financing: none disclosed.
  • Money received after Sep 30, 2026: the new $400.0M Sixth Street loan (Nov 2), used with cash on hand to repay the old loan; net of the payoff and the 2% fee it used about $12.4M (our calculation)10.

Shortens the runway:

  • Debt due within 24 months: Visirna’s Chinese bank borrowings of $6.8M, all classified as current (10-K FY2026, note 15). The new Sixth Street loan has no scheduled repayments before Nov 2, 2031, and early repayment costs a make-whole premium until May 2028, then 2% and 1% premiums until May 2030.
  • Cash interest on the new loan, at three-month SOFR (with a 1.00% floor) plus 5.50%, paid quarterly: at least $26.0M a year at the floor rate (our calculation)10. The old loan’s interest was not paid in cash, so the past rate does not include it.
  • Minimum-cash covenant: Arrowhead must keep at least $125.0M of unrestricted cash in pledged US accounts at all times (down from $150.0M under the old loan) (8-K, Nov 4).
  • The $700.0M of 0% convertible notes are due Jan 15, 2032, and the $400.4M Royalty Pharma liability is not repayable in cash (10-K FY2026, notes 14 and 16).

Conditional:

  • Visirna’s bank agreement with China ZheShang Bank allows up to CNY 70.0M (about $10.0M); its earlier facility was repaid.
  • At-the-market share-sale programme: up to $500.0M with Jefferies (amended Dec 10, 2025); $76.1M gross had been sold by Sep 30, 2026, leaving about $423.9M (our calculation)11. Uncommitted: it adds cash only if Arrowhead chooses to sell shares.
  • Further convertible debt is now permitted by the loan (see section 4); none is committed.
  • The priority review voucher can be sold, which the new loan permits without lender consent; its resale value is not known.
  • Partner milestones tied to development or sales, including up to $485.0M of remaining olpasiran milestones from Amgen and Royalty Pharma and the $100.0M GSK Phase 3 milestone. Arrowhead says it is eligible for up to $16.2B of milestones in total.

Cash path (our calculation; an illustration, not a forecast):

At the past rate and with known items, cash would fall below zero in Q2 2028 (our calculation)10; the company itself says its liquidity covers at least the next twelve months from Nov 12, 2026 (10-K), without specifying a run-out date.

Illustration, not a forecast.

Cash path: ending cash by quarter (illustration)Start $1.19B, Q4 2026 $997M, Q1 2027 $817M, Q2 2027 $630M, Q3 2027 $451M, Q4 2027 $271M, Q1 2028 $91M, Q2 2028 −$89M.Q2 2027: raising window (under a year of usual spending left)Q3 2027: raising window (under a year of usual spending left)Q4 2027: raising window (under a year of usual spending left)Q1 2028: raising window (under a year of usual spending left)Q2 2028: would need new money−$250M$0M$250M$500M$750M$1.00B$1.25BStart: $1.19BQ4 2026: $997MQ1 2027: $817MQ2 2027: $630MQ3 2027: $451MQ4 2027: $271MQ1 2028: $91MQ2 2028: −$89MStartQ4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028Q4 2026: known item −$12M (Nov 2 refinancing: $400.0M new loan less the $404.4M payoff of the old one and the $8.0M (2%) fee to lenders (10-K FY2026, note 19))1Q2 2027: known item −$7M (Visirna’s $6.8M bank borrowings, classified as current; repayment placed in this quarter by us, a year after the May 2026 agreement (no refinancing assumed) (10-K FY2026, note 15). Less than a year of usual spending left.)2
  1. 1 · Q4 2026 · Nov 2 refinancing −$12M
  2. 2 · Q2 2027 · Visirna’s $6.8M bank borrowings −$7M

Ending cash (cash, equivalents and marketable securities) Known item Raising window (under a year of usual spending left) Would need new money

Quarter Starting cash Usual spending Known items Ending cash Sources / notes
Q4 2026 +1,188.8 −179.7 −12.4 +996.6 Nov 2 refinancing: $400.0M new loan less the $404.4M payoff of the old one and the $8.0M (2%) fee to lenders (10-K FY2026, note 19)
Q1 2027 +996.6 −179.7 0.0 +816.9
Q2 2027 +816.9 −179.7 −6.8 +630.4 Visirna’s $6.8M bank borrowings, classified as current; repayment placed in this quarter by us, a year after the May 2026 agreement (no refinancing assumed) (10-K FY2026, note 15). Less than a year of usual spending left.
Q3 2027 +630.4 −179.7 0.0 +450.6 Less than a year of usual spending left.
Q4 2027 +450.6 −179.7 0.0 +270.9 Less than a year of usual spending left.
Q1 2028 +270.9 −179.7 0.0 +91.2 Below the loan’s $125.0M minimum cash. Less than a year of usual spending left.
Q2 2028 +91.2 −179.7 0.0 −88.6

Amounts in $M.

Usual spending is an even quarter’s share of the past year’s free cash flow without the one-off partner receipts, about −$179.7M a quarter, held flat (our calculation)12.

No committed undrawn financing is disclosed, so there is no “financing that could extend the runway” table for Arrowhead.

At the past rate and with known items, cash would fall below zero in Q2 2028 (our calculation)10; the company itself says its liquidity covers at least the next twelve months from Nov 12, 2026 (10-K), without specifying a run-out date. Companies usually raise money well before that; quarters with less than a year of usual spending left are shaded.

Known items in the path:

  • Q4 2026: −$12.4M net for the Nov 2 refinancing.
  • Q2 2027: repayment of Visirna’s $6.8M bank borrowings, which are current (no refinancing assumed).
  • Not dated, so not included: possible partner milestones and any sale of the voucher. Sarepta’s recurring $50.0M annual fee is already in usual spending.

Path basis:

  • Usual spending excludes the one-off partner receipts and is held flat at that adjusted past rate.
  • Cash would fall below the loan’s $125.0M minimum in Q1 2028, a quarter before it reaches zero. The covenant applies to cash in pledged US accounts; our total also includes cash at Visirna.
How we calculated this
  • Usual spending is FY2026 free cash flow (−$283.9M, Oct 2025–Sep 2026) minus the one-off receipts listed below, divided by four: about −$179.7M a quarter (our calculation)12, held flat. We exclude the receipts because they are more than 20% of the absolute free cash flow (our rule for lumpy one-off receipts).
  • Calculations use unrounded amounts (starting cash about $1,188.783M, using the disclosed rounded restricted-cash amount; quarterly spending −$179.736M); displayed values are rounded to $0.1M.
  • Starting cash is cash and cash equivalents (including cash at Visirna, excluding $4.2M of restricted cash) and available-for-sale securities at Sep 30, 2026.
  • Known items are disclosed amounts only.

One-off receipts excluded from usual spending ($435.0M in total, our calculation)12:

One-off payments: none to remove.

  • The $215.0M voucher was an investing outflow, not part of free cash flow, so there is nothing to remove for it; no licensing or acquisition upfronts or settlements were paid in FY2026.
  • Income taxes of $21.6M paid in FY2026 (on FY2025 profit) stay in usual spending as an ordinary operating outflow; removing them would not change the run-out quarters (10-K FY2026, cash flow statement).

Kept in usual spending: Sarepta’s first annual fee, $50.0M (Feb 2026). It is a contractual yearly payment (five instalments of $50.0M; the second, of up to $50.0M, is due within 12 months of Sep 30, 2026), not a one-off, so trailing free cash flow already reflects it at its normal yearly rate (10-K FY2026, MD&A).

Not included:

  • Cash interest on the new Sixth Street loan. Its amount depends on SOFR; at the 1.00% floor it would be at least $6.5M a quarter. Adding that from Q1 2027 would not change the quarter in which cash falls below the minimum (Q1 2028) or below zero (Q2 2028) (our calculation)10.
  • Possible partner milestones, because none is dated and certain: the $100.0M GSK Phase 3 milestone and others, and any sale of the voucher. (Sarepta’s annual fee is already in usual spending.)
  • Lease payments, under the no-double-counting rule: operating-lease payments ($188.8M undiscounted at Sep 30, 2026, $6.1M of it in FY2027) are in operating cash flow and therefore inside usual spending. Non-cancellable manufacturing purchase obligations of up to $57.5M are ordinary operating costs and are not added either (10-K FY2026, notes 7 and 9).
  • Capital spending is inside usual spending: FY2026 capex was $12.0M, far below FY2024’s $141.5M, when Arrowhead was building its Verona, Wisconsin manufacturing plant. Arrowhead has not quantified a new capex plan.
  • Spending to build a larger sales force for a possible sHTG launch, which Arrowhead says will require “a larger commercial footprint” but has not quantified (10-K FY2026, Item 1).

6. Customer and contract exposure

Last updated Nov 12, 2026. Reflects the 10-K FY2023, 10-K FY2025 and 10-K FY2026.

Almost all revenue has come from a few partners, and the largest one has changed every few years as deals are signed and their upfront payments are recognised.

Revenue by source (our calculation)1 FY2023 FY2024 FY2025 FY2026
Sarepta (named) – – 84.0% 70.3%
Novartis (named) – – – 19.7%
Madrigal (named) – – – 5.5%
Sanofi (named; through Visirna) – – 15.7% 3.0%
GSK (named) 12.3% 75.6% 0.3% –
Takeda (named) 67.5% 24.4% – –
Amgen (named) 10.4% – – –
Horizon (named) 9.6% – – –
Janssen (named) 0.1% – – –
Redemplo product sales – – – 1.5%
Total revenue ($M) 240.7 3.6 829.4 450.8

Sarepta and Novartis supplied 90% of FY2026 revenue; both can end their agreements on 30 days’ notice before a product is approved (details in the toggle).

Revenue by source, % of total revenue
SareptaNovartisMadrigalSanofiGSKTakedaAmgenHorizonJanssenRedemplo product salesFY2023FY2023, Sarepta: 0% of total revenueFY2023, Novartis: 0% of total revenueFY2023, Madrigal: 0% of total revenueFY2023, Sanofi: 0% of total revenueFY2023, GSK: 12.3% of total revenueFY2023, Takeda: 67.5% of total revenueFY2023, Amgen: 10.4% of total revenueFY2023, Horizon: 9.6% of total revenueFY2023, Janssen: 0.1% of total revenueFY2023, Redemplo product sales: 0% of total revenue99.9%FY2024FY2024, Sarepta: 0% of total revenueFY2024, Novartis: 0% of total revenueFY2024, Madrigal: 0% of total revenueFY2024, Sanofi: 0% of total revenueFY2024, GSK: 75.6% of total revenueFY2024, Takeda: 24.4% of total revenueFY2024, Amgen: 0% of total revenueFY2024, Horizon: 0% of total revenueFY2024, Janssen: 0% of total revenueFY2024, Redemplo product sales: 0% of total revenue100%FY2025FY2025, Sarepta: 84% of total revenueFY2025, Novartis: 0% of total revenueFY2025, Madrigal: 0% of total revenueFY2025, Sanofi: 15.7% of total revenueFY2025, GSK: 0.3% of total revenueFY2025, Takeda: 0% of total revenueFY2025, Amgen: 0% of total revenueFY2025, Horizon: 0% of total revenueFY2025, Janssen: 0% of total revenueFY2025, Redemplo product sales: 0% of total revenue100%FY2026FY2026, Sarepta: 70.3% of total revenueFY2026, Novartis: 19.7% of total revenueFY2026, Madrigal: 5.5% of total revenueFY2026, Sanofi: 3% of total revenueFY2026, GSK: 0% of total revenueFY2026, Takeda: 0% of total revenueFY2026, Amgen: 0% of total revenueFY2026, Horizon: 0% of total revenueFY2026, Janssen: 0% of total revenueFY2026, Redemplo product sales: 1.5% of total revenue100%
Show the data
Label Sarepta Novartis Madrigal Sanofi GSK Takeda Amgen Horizon Janssen Redemplo product sales Unit
FY2023 0 0 0 0 12.3 67.5 10.4 9.6 0.1 0 % of total revenue
FY2024 0 0 0 0 75.6 24.4 0 0 0 0 % of total revenue
FY2025 84.0 0 0 15.7 0.3 0 0 0 0 0 % of total revenue
FY2026 70.3 19.7 5.5 3.0 0 0 0 0 0 1.5 % of total revenue

Chart source13.

Partner terms, distribution, lender limits and litigation
  • Sarepta: can end the agreement on 30 days’ notice before any product is approved. It owes $50.0M annual fees for five years (the first was paid in February 2026; the second, of up to $50.0M, is due within 12 months of Sep 30, 2026), regulatory milestones of $110–180M per programme, sales milestones and royalties of up to the low double digits. In Q2 FY2026 it exercised its right to take over certain clinical programmes, which reduces the research work Sarepta reimburses Arrowhead for (10-K FY2026, note 2).
  • Novartis: can end the agreement on 30 days’ notice before approval, or 180 days’ notice after; most of the $113.0M of deferred revenue at Sep 30, 2026 relates to its upfront payment.
  • Other partners: Takeda shares US costs and profits of fazirsiran 50/50 and pays royalties of 20–25% outside the US. GSK owes $100.0M when it doses the first Phase 3 patient with GSK-4532990. Amgen and Royalty Pharma owe up to $485.0M of remaining olpasiran milestones; Royalty Pharma receives all olpasiran royalties. Madrigal owes up to $975.0M in milestones on ARO-PNPLA3 and royalties from high-single digits to the mid-teens. In total, Arrowhead says it is eligible for up to $16.2B of milestones across its partnered programmes (10-K FY2026, notes 1, 2 and 14).
  • Distribution: the FY2025 10-K named Vanscoy Rare Pharmacy as Arrowhead’s exclusive specialty pharmacy for Redemplo. The FY2026 10-K says Arrowhead relies on a specialty pharmacy and expects to rely on a specialty distributor for “a considerable portion” of Redemplo sales (10-K FY2025 and 10-K FY2026, risk factors). Sanofi sells Redemplo in Greater China and pays royalties.
  • Lender limits: the refinanced Sixth Street loan still restricts asset sales and licensing transactions, but expressly allows Arrowhead, without lender consent, to license Redemplo outside the US and to sell the voucher, and gives more flexibility on pipeline deals. It no longer takes a share of product sales, royalties, milestones or partnering proceeds as prepayments (8-K, Nov 4).
  • Litigation: Ionis’s ’333 patent suit (filed Sep 11, 2025) seeks damages; Ionis filed an amended complaint on Oct 1, 2026 alleging that Arrowhead’s sales of plozasiran infringe, and the court has set a trial date of Jul 11, 2028. Arrowhead disputes the claims and had recorded no liability at Sep 30, 2026 (10-K FY2026, note 7).

7. Strategy for long-term growth

Last updated Nov 12, 2026. Reflects the 10-K FY2026 and the FY2026 results release.

Arrowhead’s plan is to turn Redemplo from a rare-disease drug into a medicine for the much larger sHTG population, while licensing programmes it does not intend to sell itself to fund that shift; it gives no annual sales guidance.

  • Pressures on the core business: in FCS Redemplo competes with Ionis’s Tryngolza (olezarsen), and Ionis is suing over a patent, with a trial set for July 2028. Arrowhead cut Redemplo’s US list price to $45,000 a patient a year in May 2026. Partner revenue fell to $444.2M in FY2026 from $829.4M as Sarepta’s upfront was recognised and Sarepta took over some programmes (10-K FY2026, Item 1A and note 2; Q2 FY2026 release).
  • Strategy in management’s words: Arrowhead “continues to progressively build its commercial capabilities to support a potential launch in sHTG in 2027, which will require a larger commercial footprint”. Partnering programmes it does not intend to commercialise itself “aims to expand the reach of the Company’s technology and to provide a source of non-dilutive capital to support REDEMPLO and other wholly-owned programs through commercial stage” (10-K FY2026, Item 1).
  • Pipeline beyond plozasiran: zodasiran in Phase 3 for homozygous familial hypercholesterolemia; ARO-DIMER-PA, its first candidate silencing two genes in one molecule; and ARO-MAPT, which reached the brain after an under-the-skin injection in healthy volunteers (company) (FY2026 release).
  • Funding moves: $930M raised in January 2026, a $215.0M voucher bought in August and later kept, and the Nov 2 refinancing, which the company’s release says gives “greater strategic, financial, and operational flexibility” (FY2026 release).
  • How it is working, in numbers: Redemplo sales were $6.6M in FY2026, its first year on sale; 950 new-to-brand prescriptions by Sep 30, with about 50–60 a week since; 160 million US lives covered by payer formularies (company). Net revenue per patient is not disclosed. The sHTG sNDA has been submitted; FDA review is pending.
  • Partnering: Novartis ($200.0M upfront, Oct 2025) and Madrigal ($25.0M upfront, Jun 2026) were added in FY2026; partner revenue was 98.5% of FY2026 revenue (our calculation)1.

8. What to watch

Last updated Nov 12, 2026. Reflects the 10-K FY2026 and company releases through Nov 12, 2026.

Date Item Source
Early 2027 (date not announced) Transition report on Form 10-Q for Oct–Dec 2026: the first quarter with cash interest on the new loan, Redemplo sales and sHTG launch spending 10-K FY2026, note 19
Q2 2027 (company’s conditional launch target; FDA decision date not announced) Potential US launch of plozasiran in sHTG, subject to FDA review and approval; the STAR pilot gives a 6-month priority review, and the FDA may act at least a month before the goal date, which has not been disclosed FY2026 release
By Sep 30, 2027 Sarepta’s second annual fee, up to $50.0M 10-K FY2026, MD&A
Mid-2027 Phase 3 YOSEMITE trial of zodasiran in homozygous familial hypercholesterolemia (a rare inherited cholesterol disorder) expected to complete FY2026 release
Jul 11, 2028 Trial date in Ionis’s ’333 patent suit over plozasiran 10-K FY2026, note 7
Nov 2, 2031 The $400.0M Sixth Street loan is due in full; the $700.0M convertible notes follow on Jan 15, 2032 10-K FY2026, notes 16 and 19

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 28, 2026$58.02 (Oct 23)$8.2B$7.5B†12.2×11.1×n/mn/m+17%−11%$735M†12 months to Jun 30, 2026
Nov 12, 2026$47.15 (Nov 12)$6.7B$6.4B†14.8×14.1×n/mn/m−46%−63%$303M†FY2026 (year to Sep 30, 2026)

Our calculation from each update's filings (latest at the newest update: 10-K for the fiscal year to Sep 30, 2026, filed Nov 12, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 28, 2026: † Debt excludes the $392.5M Royalty Pharma liability, not repayable in cash, which the company reports separately; debt includes $3.2M of Visirna bank borrowing, reported in other current liabilities. Nov 12, 2026: † Debt excludes the $400.4M Royalty Pharma liability, not repayable in cash, which the company reports separately; debt includes $6.8M of Visirna bank borrowings, reported in other current liabilities. Oct 28, 2026 row: Corrected Nov 2, 2026: debt now includes Arrowhead's line of credit ($141.4M, plus $40.0M due within a year); debt $864.1M (was $682.7M), net cash $737.9M (was $919.3M), enterprise value $7.45B (was $7.27B) and EV/sales 11.1× (was 10.9×). Price and date unchanged. Updated Nov 12, 2026: debt now also includes Visirna's $3.2M bank borrowing, reported in other current liabilities; debt $867.3M (was $864.1M) and net cash $734.7M (was $737.9M); enterprise value ($7.45B) and EV/sales (11.1×) are unchanged at their rounding. Price and date unchanged. Oct 28, 2026 price: the Long View's stated close (Yahoo Finance). Nov 12, 2026 price: Nasdaq historical close.

Notes and calculations

Section sources:

  1. Revenue by source ÷ total revenue × 100, from the revenue tables in note 2 of the 10-K FY2023 (FY2023), 10-K FY2025 (FY2024) and 10-K FY2026 (FY2025–26). FY2026: Sarepta $316.886M ÷ $450.817M ≈ 70.3%; Novartis $89.010M ≈ 19.7%; Madrigal $25.000M ≈ 5.5%; Sanofi $13.318M ≈ 3.0%; product sales $6.603M ≈ 1.5%; partner revenue $444.214M ≈ 98.5%. FY2025: Sarepta $696.803M ÷ $829.448M ≈ 84.0%. FY2023: Janssen $0.356M ÷ $240.7M ≈ 0.1%. ↩ ↩2 ↩3

  2. Q4 FY2026 = FY2026 (10-K FY2026) − 9M FY2026 (10-Q Q3 FY2026). Product sales: $6.603M − $3.501M = $3.102M ≈ $3.1M (9M product sales = total revenue $413.023M − collaboration revenue $409.522M). Q3 FY2026 product sales: $75.253M − $72.868M ≈ $2.4M. Partner revenue: $444.214M − $409.522M = $34.692M; Sarepta $316.886M − $297.594M = $19.292M; Novartis $89.010M − $74.945M = $14.065M. Operating expenses $1,157.988M − $683.567M = $474.421M; without the $215.0M voucher $259.421M. Net loss attributable to Arrowhead −$724.206M − (−$296.205M) = −$428.001M. ↩ ↩2 ↩3

  3. Cash and restricted cash + cash at Visirna + available-for-sale securities. Sep 30, 2026: $29.278M + $33.457M + $1,130.248M = $1,192.983M ≈ $1,193.0M (including $4.2M of restricted cash). Jun 30, 2026: $19.685M + $35.074M + $1,547.201M = $1,601.960M ≈ $1,602.0M (balance sheets in the 10-K and 10-Q). ↩

  4. Common shares outstanding 104.327M (Sep 30, 2021) and 141.290M (Sep 30, 2026). Growth = (141.290 ÷ 104.327 − 1) × 100 ≈ 35%; annual growth = [(141.290 ÷ 104.327)^(1 ÷ 5) − 1] × 100 ≈ 6.3%; remaining ownership = 1% × 104.327 ÷ 141.290 ≈ 0.74%; offset = 2.661M shares returned ÷ 39.624M new common shares issued (8.836M from equity plans + 30.788M sold for cash) ≈ 7%. FY2026 equity plans: 0.642M from options + 1.874M from vested stock units = 2.516M; share sales: 1.056M at the market + 2.016M in the follow-on = 3.072M. Including pre-funded warrants: 141.290M + 2.468M = 143.758M; growth = (143.758 ÷ 104.327 − 1) × 100 ≈ 38%; annual growth = [(143.758 ÷ 104.327)^(1 ÷ 5) − 1] × 100 ≈ 6.6%. ↩ ↩2

  5. Average price = gross proceeds ÷ shares. FY2025: ($325.0M + $25.0M) ÷ 12.844M ≈ $27.25. FY2026: ($130.0M + $100.0M + $76.1M) ÷ (2.016M + 1.550M + 1.056M) = $306.1M ÷ 4.622M ≈ $66.23. At-the-market sales: $76.109M ÷ 1.056M ≈ $72.07. ↩ ↩2

  6. Stock-based compensation ÷ revenue × 100. Stock pay (cash flow statements): FY2022 $120.9M, FY2023 $78.1M, FY2024 $74.0M, FY2025 $63.4M, FY2026 $68.1M. Revenue: FY2022 $243.2M, FY2023 $240.7M, FY2024 $3.6M, FY2025 $829.4M, FY2026 $450.8M. ↩

  7. Free cash flow = operating cash flow + the capital-spending outflow (10-K FY2026, cash flow statement). FY2026: −$271.949M − $11.995M = −$283.944M; FY2025: $179.552M − $22.666M = $156.886M. The $215.0M voucher purchase is an investing outflow and is not capital spending. ↩

  8. $200.0M + $200.0M + $50.0M + $10.0M + $25.0M = $485.0M, from the amounts and dates disclosed in note 2 and the MD&A of the 10-K FY2026. ↩ ↩2

  9. Cash for the runway: $29.278M + $33.457M + $1,130.248M − $4.2M restricted ≈ $1,188.8M. Excluding one-off receipts (the $485.0M of note 8 less Sarepta’s recurring $50.0M annual fee = $435.0M): $1,188.8M ÷ ($283.944M + $435.0M) = $1,188.8M ÷ $718.9M ≈ 1.7 years. Unadjusted (including them): $1,188.8M ÷ $283.944M ≈ 4.2 years. Based on past cash flow; spending plans can change it. ↩

  10. Refinancing, net: +$400.0M − $404.4M − 2% × $400.0M ($8.0M) = −$12.4M. Adjusted path: $1,188.8M start, −$179.7M a quarter, plus known items (−$12.4M in Q4 2026; −$6.8M in Q2 2027). Ending cash: Q4 2027 $270.9M, Q1 2028 $91.2M (below the $125.0M minimum), Q2 2028 −$88.6M. With floor-rate interest of (1.00% + 5.50%) × $400.0M ÷ 4 = $6.5M a quarter from Q1 2027: Q1 2028 $58.7M, Q2 2028 −$127.6M, the same quarters. Unadjusted result (usual spending −$71.0M a quarter, same known items): cash would fall below the $125.0M minimum in Q2 2030 and below zero in Q4 2030 (about −$37.2M). ↩ ↩2 ↩3 ↩4

  11. $500.0M programme − $76.1M gross sold ≈ $423.9M. ↩

  12. One-off receipts excluded: $200.0M + $200.0M + $10.0M + $25.0M = $435.0M (all of note 8 except Sarepta’s recurring $50.0M annual fee). They are about 1.5 times the absolute FY2026 free cash flow ($435.0M ÷ $283.944M), far above the 20% threshold. Usual spending = (−$283.944M − $435.0M) ÷ 4 ≈ −$179.7M a quarter. Unadjusted: −$283.944M ÷ 4 ≈ −$71.0M a quarter. ↩ ↩2 ↩3

  13. Chart source: the revenue table above. Chart values are the percentages in the “Revenue by source” table (dashes shown as 0); FY2024 total revenue was only $3.6M, so its percentages rest on a small base. ↩

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About Arrowhead Pharmaceuticals: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)